Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Mitogen-Activated Protein Kinase Kinases × Clear all
NCT02069730 2026-01-08

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

University Health Network, Toronto

Phase NA Completed
114 enrolled
Head & Neck

Neoplasm Metastasis, Neoplasms, Recurrence, Salivary Gland Neoplasms

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
43 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡